Second Half Financial Partners LLC Buys Shares of 10,591 Amgen Inc. (NASDAQ:AMGN)

Second Half Financial Partners LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,591 shares of the medical research company’s stock, valued at approximately $3,413,000. Amgen accounts for approximately 1.8% of Second Half Financial Partners LLC’s investment portfolio, making the stock its 14th largest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Amgen in the 3rd quarter worth approximately $16,969,000. Fifth Third Wealth Advisors LLC boosted its stake in Amgen by 27.0% in the third quarter. Fifth Third Wealth Advisors LLC now owns 4,334 shares of the medical research company’s stock valued at $1,396,000 after acquiring an additional 922 shares in the last quarter. BIP Wealth LLC grew its holdings in Amgen by 4.1% in the third quarter. BIP Wealth LLC now owns 1,108 shares of the medical research company’s stock worth $357,000 after purchasing an additional 44 shares during the last quarter. Prospera Financial Services Inc grew its holdings in Amgen by 28.1% in the third quarter. Prospera Financial Services Inc now owns 30,373 shares of the medical research company’s stock worth $9,788,000 after purchasing an additional 6,662 shares during the last quarter. Finally, Smead Capital Management Inc. increased its position in shares of Amgen by 3.5% during the third quarter. Smead Capital Management Inc. now owns 1,172,866 shares of the medical research company’s stock worth $377,909,000 after purchasing an additional 39,559 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research analyst reports. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Citigroup assumed coverage on shares of Amgen in a report on Thursday, November 14th. They set a “neutral” rating and a $335.00 price objective on the stock. Wolfe Research assumed coverage on shares of Amgen in a research note on Friday. They issued a “peer perform” rating for the company. Finally, Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and upped their price target for the company from $320.00 to $333.00 in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average target price of $333.57.

Amgen Trading Down 0.9 %

Shares of Amgen stock opened at $278.76 on Tuesday. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market cap of $149.84 billion, a P/E ratio of 35.69, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. The firm has a 50-day simple moving average of $319.90 and a two-hundred day simple moving average of $318.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.96 earnings per share. As a group, equities analysts predict that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.23%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.